<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141931</url>
  </required_header>
  <id_info>
    <org_study_id>SOVS2016-045</org_study_id>
    <nct_id>NCT03141931</nct_id>
  </id_info>
  <brief_title>The Effects of Dietary Supplementation With Omega-3 Fatty Acids on Symptoms of Dry Eye</brief_title>
  <official_title>The Effects of Dietary Supplementation With a Combination of Flaxseed Oil, Borage Oil and Fish Oil Omega-3 Fatty Acids on Ocular Comfort Including Symptoms of Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare ocular symptoms and signs when the test nutraceutical
      formulation (combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids) is
      consumed daily over a 3 month period, with a control capsule that contains polyethylene
      glycol (PEG), oleic acid and propylene glycol, which are found in many pharmaceutical
      products and are generally considered to be biologically inert and safe. There is good
      evidence that the consumption of oily fish has a protective effect against dry eye, and other
      studies have provided evidence of the beneficial effect of supplementation with omega-3
      essential fatty acids in the treatment of dry eye disease. However, there have been limited
      well designed clinical trials investigating the potential for nutraceutical dietary
      supplementation to impact ocular comfort. To date, no controlled, randomised clinical trials
      have been conducted to evaluate the test nutraceutical formulation. Therefore, the purpose of
      this study is to conduct a randomized, placebo-controlled, double-masked study to investigate
      the effects of dietary supplementation with a combination of flaxseed oil, borage oil and
      fish oil omega-3 fatty acids on ocular comfort including signs and symptoms of dry eye.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, randomised, placebo-controlled, double masked study
      conducted over a 3-month period. One hundred and thirty-eight (138) participants who meet the
      inclusion / exclusion criteria and give informed consent will be randomised to either the
      test capsules containing a combination of flaxseed oil, borage oil and fish oil omega-3 fatty
      acids or placebo capsules, identical in appearance, containing polyethylene glycol, oleic
      acid and propylene glycol (found in many pharmaceutical products and considered to be
      biologically inert and safe) to be taken by mouth three times daily for 40 days, and then
      twice daily thereafter for approximately 50 days. Every effort will be made to stratify
      enrolment by disease severity to ensure participants with mild, moderate and severe dry eye
      are represented in the study population. Stratification will be in a 2:2:1 fashion i.e. OSDI
      score &gt;12 (55 participants), OSDI score &gt;20 (55 participants) and OSDI score &gt;45 (28
      participants). Participants will be stratified according to dry eye severity prior to
      randomisation. There will be a total of 3 scheduled study visits over a period of
      approximately 3 months - Day 1, 1 month and 3 months. Ocular comfort and symptoms of dry eye
      will be assessed via questionnaires. The tear film and ocular surface will be assessed using
      specialised instruments including the slit lamp biomicroscope, Lipiview Ocular Surface
      Interferometer, Vapometer and Oculus Keratograph 5M, and stains. Safety will be assessed
      through measurement of vision, ocular redness and evaluation of the ocular surface using the
      slit lamp biomicroscope. Those participants who meet the eligibility criteria will be
      randomly allocated to either the test or control capsules. An adequate supply of capsules
      will be dispensed to last until the next Participants will be instructed to ingest one
      capsule three times daily with meals for 40 days, and then two times daily until their final
      3 month study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Actual">October 19, 2018</completion_date>
  <primary_completion_date type="Actual">October 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Ocular Symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Measured using the Ocular Surface Disease Index questionnaire. Ocular surface disease index is assessed on a scale of 0 to 100 with higher score representing greater disability. Scores can range from 10 to 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Ocular Comfort</measure>
    <time_frame>3 months</time_frame>
    <description>Measured using the Ocular Comfort Index questionnaire. Ocular comfort index questionnaire score range from 0 to 72. Lowest slow indicates better subjective symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Ocular Dryness</measure>
    <time_frame>3 months</time_frame>
    <description>Measured using the Dry Eye Questionnaire 5. Dry eye questionnaire 5 score ranges from 0 to 22.
Lower score represents better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive Tear Film Break-up Time</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in seconds using the Oculus Keratograph. Higher value represents better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Evaporation Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in g.m^2.h using the Vapometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Meniscus Height</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in millimeters using the Oculus Keratograph 5M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Volume</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in millimeters using phenol red thread tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Lipid Layer Thickness</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in nanometers using the LipiView ocular surface interferometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Polyethylene glycol, Oleic acid, Propylene glycol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supplement</intervention_name>
    <description>Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
    <arm_group_label>Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read and comprehend English and give informed consent as demonstrated by
             signing a record of informed consent;

          -  Be at least 18 years old;

          -  Have symptoms of ocular discomfort as measured with the Ocular Surface Disease Index
             (OSDI) score of &gt;12 at the Baseline visit;

          -  Willing to comply with the dosage and study visit schedule as directed by the
             investigator;

          -  No contact lens wear in the last 30 days and willing to refrain from contact lens wear
             for the duration of the study;

          -  No planned changes to diet and willing not to substantially alter their usual diet for
             the duration of the study, including their typical intake of fish;

          -  Willingness to notify the study investigator if instructed to alter their diet by
             health/medical practitioner;

          -  Willing to continue using any artificial tear supplements at the same frequency
             throughout the study, as used prior to the study

          -  Have health and ocular health findings which would not prevent the participant from
             safely ingesting dietary supplementation with combination omega oils

        Exclusion Criteria:

          -  Any systemic disease that would preclude participants from safely ingesting dietary
             supplementation with combination omega oils;

          -  Self-reported allergy/sensitivity to any of the study product ingredients;

          -  Use of any polyunsaturated fatty acid-containing dietary supplements (such as fish
             oil, evening primrose oil, linseed oil) up to 12 weeks prior to the start of the
             study;

          -  Use of any of the following medications (including steroids) up to 12 weeks prior to
             start of the study or during the course of the study:

               -  Ocular medication, category S3 and above;

               -  Any systemic or topical medications that will affect ocular physiology e.g.
                  anti-acne medications such as Roaccutane and corticosteroid or immunosuppressant
                  medications such as Hydrocortisone, Prednisolone and antihistamine medications
                  such as Claritine;

          -  Any systemic disease that may affect ocular health e.g. Graves disease, and
             auto-immune diseases such as ankolysing spondylitis, multiple sclerosis and systemic
             lupus erythematosis;

          -  Epilepsy or history of migraines exacerbated by flashing, strobe-like lights;

          -  Eye surgery within 6 months immediately prior to enrolment for this study;

          -  Rigid or soft contact lens wearer, including orthokeratology in the last 30 days;

          -  Previous corneal refractive surgery;

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Tan-Showyin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New South Wales</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Optometry and Vision Science</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>May 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of New South Wales</investigator_affiliation>
    <investigator_full_name>Jacqueline Tan-Showyin</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Nutraceutical supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Any data included in reports, publications or presented at meetings will be provided in the form of group responses or study identity numbers, such that the participants cannot be identified.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03141931/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lacritec</title>
          <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Supplement</title>
          <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="18.2"/>
                    <measurement group_id="B2" value="44.1" spread="19.2"/>
                    <measurement group_id="B3" value="41.43" spread="18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular Surface Disease Index</title>
          <description>Ocular Surface Disease Index score ranges from 5 to 100. Lower scores indicates better subjective symptoms (better outcomes).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="21.6" upper_limit="52.4"/>
                    <measurement group_id="B2" value="36" lower_limit="20.4" upper_limit="51.6"/>
                    <measurement group_id="B3" value="36" lower_limit="20.4" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular Comfort Index</title>
          <description>Ocular Comfort Index score ranges from 0 to 100. Lower scores indicates better subjective symptoms (better outcomes).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" lower_limit="25.20" upper_limit="47.6"/>
                    <measurement group_id="B2" value="38.9" lower_limit="32.50" upper_limit="45.30"/>
                    <measurement group_id="B3" value="39.0" lower_limit="30.35" upper_limit="47.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dry Eye Questionnaire - 5</title>
          <description>Dry Eye Questionnaire score ranges from 0 to 100. Lower scores indicates better subjective symptoms (better outcomes).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.43" lower_limit="9.33" upper_limit="15.53"/>
                    <measurement group_id="B2" value="11.5" lower_limit="8.3" upper_limit="14.70"/>
                    <measurement group_id="B3" value="11.80" lower_limit="8.45" upper_limit="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-invasive tear break-up time</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="5.1"/>
                    <measurement group_id="B2" value="12.0" spread="6.4"/>
                    <measurement group_id="B3" value="11.70" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tear Evaporation</title>
          <description>Tear evaporation rate ranges from 20 to 200. Lower scores indicates better subjective symptoms (better outcomes).</description>
          <units>g.m^2.h</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.03" lower_limit="32.17" upper_limit="83.89"/>
                    <measurement group_id="B2" value="58.36" lower_limit="32.48" upper_limit="84.24"/>
                    <measurement group_id="B3" value="58.24" lower_limit="33.64" upper_limit="82.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Ocular Symptoms</title>
        <description>Measured using the Ocular Surface Disease Index questionnaire. Ocular surface disease index is assessed on a scale of 0 to 100 with higher score representing greater disability. Scores can range from 10 to 100.</description>
        <time_frame>3 months</time_frame>
        <population>All participant received at-least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ocular Symptoms</title>
          <description>Measured using the Ocular Surface Disease Index questionnaire. Ocular surface disease index is assessed on a scale of 0 to 100 with higher score representing greater disability. Scores can range from 10 to 100.</description>
          <population>All participant received at-least one dose of treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.42" lower_limit="11.18" upper_limit="43.66"/>
                    <measurement group_id="O2" value="27.43" lower_limit="11.8" upper_limit="43.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Ocular Comfort</title>
        <description>Measured using the Ocular Comfort Index questionnaire. Ocular comfort index questionnaire score range from 0 to 72. Lowest slow indicates better subjective symptoms.</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ocular Comfort</title>
          <description>Measured using the Ocular Comfort Index questionnaire. Ocular comfort index questionnaire score range from 0 to 72. Lowest slow indicates better subjective symptoms.</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.61" lower_limit="27.08" upper_limit="44.14"/>
                    <measurement group_id="O2" value="35.66" lower_limit="27.11" upper_limit="44.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Ocular Dryness</title>
        <description>Measured using the Dry Eye Questionnaire 5. Dry eye questionnaire 5 score ranges from 0 to 22.
Lower score represents better outcome.</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ocular Dryness</title>
          <description>Measured using the Dry Eye Questionnaire 5. Dry eye questionnaire 5 score ranges from 0 to 22.
Lower score represents better outcome.</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" lower_limit="5.81" upper_limit="13.69"/>
                    <measurement group_id="O2" value="9.78" lower_limit="5.89" upper_limit="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-invasive Tear Film Break-up Time</title>
        <description>Measured in seconds using the Oculus Keratograph. Higher value represents better outcome.</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-invasive Tear Film Break-up Time</title>
          <description>Measured in seconds using the Oculus Keratograph. Higher value represents better outcome.</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" lower_limit="5.84" upper_limit="17.16"/>
                    <measurement group_id="O2" value="11.49" lower_limit="5.88" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Evaporation Rate</title>
        <description>Measured in g.m^2.h using the Vapometer</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Evaporation Rate</title>
          <description>Measured in g.m^2.h using the Vapometer</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>g.m^2.h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.10" spread="25.41"/>
                    <measurement group_id="O2" value="59.11" spread="25.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Meniscus Height</title>
        <description>Measured in millimeters using the Oculus Keratograph 5M</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Meniscus Height</title>
          <description>Measured in millimeters using the Oculus Keratograph 5M</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.10"/>
                    <measurement group_id="O2" value="0.27" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Volume</title>
        <description>Measured in millimeters using phenol red thread tests</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Volume</title>
          <description>Measured in millimeters using phenol red thread tests</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.17" spread="6.73"/>
                    <measurement group_id="O2" value="18.13" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Film Lipid Layer Thickness</title>
        <description>Measured in nanometers using the LipiView ocular surface interferometer</description>
        <time_frame>3 months</time_frame>
        <population>All participants received at least one dose of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lacritec</title>
            <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Lipid Layer Thickness</title>
          <description>Measured in nanometers using the LipiView ocular surface interferometer</description>
          <population>All participants received at least one dose of treatment.</population>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.59" spread="20.33"/>
                    <measurement group_id="O2" value="64.84" spread="19.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lacritec</title>
          <description>Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
Lacritec: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Polyethylene glycol, Oleic acid, Propylene glycol
Placebo: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive issues</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>To manufacture the placebo soft gel capsule, inclusion of oleic acid in the formulation was required, which could have an influence on the placebo arm of the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Jacqueline Tan</name_or_title>
      <organization>University of New South Wales</organization>
      <phone>+61 (02) 9385 6551</phone>
      <email>jacqueline.tan@unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

